TED STEWART, District Judge.
This matter is before the Court on Plaintiffs' Motion In Limine to Exclude Photos Not Disclosed In Discovery. For the following reasons, the Court denies the Motion.
On December 6, 2017, more than two years after the close of discovery, Xymogen produced a number of photographs identified as XYMOGEN000675-842 (the "Photos"). Plaintiffs (collectively "Thorne") filed this Motion to preclude Xymogen from "offering any evidence, testimony, or argument regarding the documents bates numbered XYMOGEN000675-842 because Xymogen failed to produce these documents during discovery and Xymogen has no justification for the untimely production."
"If a party fails to provide information or identify a witness as required by Rule 26(a) or (e), the party is not allowed to use that information or witness to supply evidence on a motion, at a hearing, or at a trial, unless the failure was substantially justified or is harmless."
Each of the above-stated factors weighs in favor of allowing the Photos. First, Xymogen argues that Thorne has not been prejudiced or surprised by the disclosure of these Photos because the Photos merely depict images of formulations, which Thorne has been aware of since 2014. The formulations were introduced during Mr. Rumolo's videotaped deposition in November 2014. Thorne's counsel was present at Mr. Rumolo's deposition, examined the formulations, and had an opportunity to question Mr. Rumolo regarding the formulations. Thorne was, therefore, aware of the formulations and the video footage of the formulations. As argued by Xymogen, Xymogen could present the video footage of Mr. Rumolo's deposition to the jury at trial instead of the Photos. However, Xymogen contends that "using the photographs in the courtroom will be much more efficient than playing minutes of videotape to show the same vials and bags of softgels."
Second, because the Court finds the prejudice to the party is minimal, the ability of Thorne to cure the prejudice is irrelevant. And third, because Thorne was aware of the formulations and Xymogen has the option of presenting the same material by use of a different medium, presentation of the Photos would not disrupt trial.
Regarding the final factor, Xymogen contends it acted in good faith in disclosing the Photos as soon as they were obtained. Xymogen was under the impression it would be able to obtain and present Mr. Rumolo's actual formulations. The formulations are maintained at National Vitamin Company in Nevada. In Fall 2017, Thorne sought to obtain the lab notebooks and formulations used at Dr. Rumolo's deposition. Thorne was informed that National Vitamin Company would not allow them to take the formulations, but would allow Thorne to inspect, photograph, and take video footage of the formulations. Shortly thereafter, Xymogen obtained Photos of the formulations and disclosed them to Thorne. The Court agrees that such action does not amount to bad faith, especially in light of the fact that Thorne was already aware of the formulations.
Upon consideration of each of the above-listed factors, the Court finds that admittance of the Photos into evidence would be harmless and will therefore allow Xymogen to present the Photos at trial.
It is therefore
ORDERED that Plaintiffs' Motion In Limine to Exclude Photos Not Disclosed In Discovery (Docket No. 268) is DENIED.